Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics, Inc. (ALLO) announced that Geoffrey Parker, its Executive Vice President, Chief Financial Officer and principal financial officer, has notified the company of his retirement from all positions. His retirement will be effective November 6, 2026, following notice given on August 31, 2026. The report is signed by President and Chief Executive Officer Zachary Roberts, M.D., Ph.D.
Allogene Therapeutics, Inc. (ALLO) reported that officer Douglas Earl Martin, SVP and General Counsel, sold 29,697 shares of common stock on August 21, 2026 at $2.12 per share. The shares were sold to cover tax withholding on vesting RSUs under a mandated "sell to cover" arrangement, so the trade was not discretionary. After this and related adjustments, including forfeiture of performance RSUs and prior ESPP purchases, he directly holds 488,267 shares of Allogene common stock.
Allogene Therapeutics, Inc. (ALLO) is the issuer of common stock for which Douglas Earl Martin, an officer, has filed a notice under Rule 144 to sell up to 29,697 shares of common stock through Morgan Stanley Smith Barney LLC on or after 08/21/2026, with an aggregate market value of $62,957.64. The shares relate to a restricted stock unit award, with 81,719 shares vesting on 08/20/2026 as part of the issuer's equity compensation plan.
Allogene Therapeutics, Inc. received an amended Schedule 13G filing reporting the beneficial ownership of its Common Stock by multiple Frazier Life Sciences investment entities and two individuals. The filing states that Frazier Life Sciences Public Fund, L.P. directly holds 19,445,046 shares of Common Stock, representing 5.6% of the class, based on 345,154,561 shares outstanding as of May 11, 2026.
Additional Frazier Life Sciences funds directly hold 306,906, 753,251, and 1,941,465 shares, with related ownership percentages of 0.1%, 0.2%, and 0.6%, respectively. James N. Topper and Patrick J. Heron share voting and investment power over the 306,906 shares held by Frazier Life Sciences X, L.P., while the filing includes customary disclaimers that it does not constitute an admission of beneficial ownership beyond what is specifically described.
Allogene Therapeutics, Inc. filed a Form S-3 shelf registration allowing it to offer and sell, from time to time after effectiveness, up to $500,000,000 of common stock, preferred stock, debt securities and warrants, including securities issuable upon conversion or exercise. This is a primary shelf for future capital-raising transactions, with specific terms (security type, amount, pricing and ranking) to be detailed in accompanying prospectus supplements for each takedown.
Allogene is a clinical-stage immuno-oncology company developing genetically engineered allogeneic “off‑the‑shelf” T cell product candidates for cancer and autoimmune diseases. Net proceeds from any offerings are intended for general corporate purposes, including clinical trials, research and development, general and administrative expenses, capital expenditures, and potentially in‑licensing or acquiring complementary businesses, assets or technologies. Allogene’s common stock trades on the Nasdaq Global Select Market under the symbol ALLO, and the last reported sale price was $2.12 per share on August 11, 2026.
Allogene Therapeutics, Inc. reported a Q2 2026 net loss of $42.7 million, improved from $50.9 million a year earlier, on collaboration revenue of $4.6 million from terminating its Overland Therapeutics license. Operating expenses fell to $51.6 million from $56.8 million, driven mainly by lower research and development spending.
Cash, cash equivalents and investments totaled $423.6 million as of June 30, 2026, supported by a $187.9 million April 2026 public equity offering and $20.7 million raised via at-the-market sales. The company expects this liquidity to fund operations into the first quarter of 2029, while still acknowledging the need for additional capital to fully execute its plans.
Allogene continues to focus on three core programs: the pivotal ALPHA3 trial of cema‑cel in first‑line large B‑cell lymphoma, the TRAVERSE Phase 1b trial of ALLO‑316 in renal cell carcinoma, and the RESOLUTION Phase 1 autoimmune basket study of ALLO‑329 using its Dagger® platform to potentially reduce or eliminate standard lymphodepletion.
Allogene Therapeutics, Inc. reported second quarter 2026 results and key clinical updates. The pivotal Phase 2 ALPHA3 trial in first-line large B-cell lymphoma showed interim minimal residual disease (MRD) data at the protocol-defined cutoff: 58.3% (7/12) of patients in the cema-cel arm achieved MRD negativity versus 16.7% (2/12) in the observation arm, a 41.6% absolute difference. Following review of this futility analysis, the FDA granted RMAT and Fast Track designations for cema-cel as first-line consolidation therapy in high-risk LBCL.
The company has already activated more than 80 ALPHA3 sites and now expects about 100 sites by year-end 2026, with enrollment of approximately 220 MRD+ patients projected to complete by year-end 2027 and an event-free survival update anticipated in mid-2027. In autoimmune disease, the Phase 1 RESOLUTION trial of ALLO-329 continues brisk enrollment, with a clinical and translational update expected in Q4 2026.
For Q2 2026, Allogene reported $4.64 million in collaboration revenue, $30.7 million in research and development expense and $20.8 million in general and administrative expense. Net loss was $42.7 million, or $0.13 per share, compared with $50.9 million a year earlier. Cash, cash equivalents and investments totaled $423.6 million as of June 30, 2026, and the company projects its cash runway into 2029. 2026 operating expense guidance is approximately $165 million (GAAP operating expenses about $225 million, including roughly $35 million of non-cash stock-based compensation).
Allogene Therapeutics, Inc. reports that investor and director Arie Belldegrun and affiliated entities have amended their passive ownership report. As of May 11, 2026, Dr. Belldegrun beneficially owns 13,610,578 shares of Allogene common stock, representing 3.9% of the 345,154,561 shares outstanding. His total includes 4,010,524 shares issuable within 60 days upon exercise of stock options and shares held through Bellco Legacy entities and Vida Ventures funds. The filing confirms that each reporting person now owns 5% or less of the outstanding common stock, with joint filing across the listed entities.
State Street Corporation reported beneficial ownership of 19,025,826 shares of Allogene Therapeutics, Inc. common stock on a Schedule 13G. This represents 5.5% of the class of Allogene’s common shares.
State Street reports no sole voting or dispositive power, with shared voting power over 18,772,433 shares and shared dispositive power over 19,025,826 shares. Subsidiaries involved include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company.